RxDoctor Payments Data

Ann Faucheux, PA

Physician Assistant · Lone Tree, CONPI 1841551157

Payments from drug & device makers

$6,288in general payments, 2019–2025

Across 296 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$597
  • Regeneron Healthcare Solutions, Inc.$500
  • Takeda Pharmaceuticals U.S.A., Inc.$440
  • Lilly USA, LLC$381
  • Johnson & Johnson$365
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,275100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,288 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$65,621
Medicare patients
192
Services billed
2,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$114,433
XifaxanRifaximin12$26,473
LinzessLinaclotide24$20,607
ZenpepLipase/Protease/Amylase11$16,995
Mesalamine14$6,611
Budesonide DrBudesonide22$5,446
DexilantDexlansoprazole12$3,728
Ursodiol20$2,642
Omeprazole160$2,343
Pantoprazole Sodium111$1,523
Colestipol Hcl14$985
Esomeprazole Magnesium15$569
Azathioprine13$317
Amitriptyline Hcl25$251
Ondansetron OdtOndansetron11$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$127$114,43312 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$597$26,47312 claims
AbbVieLinzess$1,849$20,60724 claims
Aimmune Therapeutics, Inc.Zenpep$14$16,99511 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$440$3,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →